Appropriate Pharmacotherapy for Inflammatory Bowel Disease


Project Status:
Project Line:
Health Technology Review
Project Sub Line:
Technology Review
Project Number:
HO0003-000 - HE0018-000

In 2018, around 270,000 Canadians were living with inflammatory bowel disease (IBD), which comprises Crohn’s disease and ulcerative colitis. Several drug classes, including corticosteroids, immunomodulators and anti-inflammatory biologics, can induce and maintain remission of IBD. CADTH has undertaken a series of reviews of the clinical and economic evidence surrounding drugs for IBD to clarify their relative place in therapy and inform appropriate reimbursement criteria by public drug plans.